(Q33367059)

26 July 2017

title

Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma (English)

1 reference

26 July 2017

1 reference

David M O'Malley

1

1 reference

26 July 2017

Masoud Azodi

2

1 reference

26 July 2017

Anita Makkenchery

3

1 reference

26 July 2017

Jacob Tangir

4

1 reference

26 July 2017

Jessica McAlpine

5

1 reference

26 July 2017

Michael Kelly

6

1 reference

26 July 2017

Peter Schwartz

7

1 reference

26 July 2017

Thomas Rutherford

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

98

1 reference

26 July 2017

issue

2

1 reference

26 July 2017

page(s)

242-248

1 reference

26 July 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel-Platinum?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Relapsed ovarian cancer: challenges and management strategies for a chronic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Update on the role of topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Management of treatment-related toxicity in advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase I and pharmacologic study of topotecan in patients with impaired renal function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Three-consecutive-day topotecan is an active regimen for recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: A Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Gemcitabine as a single-agent treatment for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Comparative activity of oral and parenteral topotecan in murine tumor models: efficacy of oral topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose-finding study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

A weekly regimen of cisplatin, paclitaxel and topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

A phase I study of weekly topotecan and Paclitaxel in previously treated epithelial ovarian carcinoma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.04.032

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2005.04.032

1 reference

26 July 2017

1 reference